COVID-19 Notice:
To protect you and the research staff during study visits, we will use all mandated health protection procedures, including wearing face masks and social distancing if required.
Blog
The first set of results from the study is now available and can be accessed here.
- Posted on Apr 9, 2023
The paper has not yet been peer-reviewed or accepted for publication. The first set of results from the study is now available and can be accessed here: https://medrxiv.org/cgi/content/short/2023.04.08.23288320v1.
ADVANCE Study – Thank you!
- Posted on Sep 30, 2022
Vitalant, OneBlood and the American Red Cross extend a thank you to the LGBTQ+ community centers, participants and countless advocates who supported the groundbreaking ADVANCE Study as we seek to make blood donation a more inclusive process.
The study aims to evaluate alternatives to the blood donor deferral policy known as men who have sex with men, or MSM.
- Posted on Jan 18, 2022
FDA-funded study aims to lift restrictions on blood donation for gay, bisexual men
Study Launched to Determine Risk of Blood Donated by Sexually Active Gay Men
- Posted on Jan 9, 2022
A blood shortage exacerbated by the COVID pandemic is adding support to an effort to change the FDA’s longstanding ban on donations by sexually active gay men.
ADVANCE Study reexamines blood donations policy for gay and bisexual men
- Posted on Jul 16, 2021
The country’s leading blood bank, Vitalant, OneBlood, and The American Red Cross, are participating in a new study that might
Nation’s largest blood centers collaborate on study into FDA’s ‘men who have sex with men’ deferral policies
- Posted on Jul 1, 2021
LGBTQ+ groups hopeful research effort leads to expanded blood donor eligibility
(doesn’t appear on English version of website) Nation’s Largest Blood Centers Conducting Innovative Research
- Posted on May 18, 2021
SAN FRANCISCO and ORLANDO, Fla. and WASHINGTON, May 18, 2021 /PRNewswire/ — Three of the nation’s largest blood centers have launched a pilot study through a contract funded by the U.S. Food and Drug Administration (FDA) that could
